2023
Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study
ESCUDERO-MARTINEZ, Irene, Marius MATUSEVICIUS, Ana PAVIA-NUNES, Petr SEVCIK, Miroslava NEVSIMALOVA et. al.Základní údaje
Originální název
Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study
Autoři
ESCUDERO-MARTINEZ, Irene (garant), Marius MATUSEVICIUS, Ana PAVIA-NUNES, Petr SEVCIK (203 Česká republika), Miroslava NEVSIMALOVA (203 Česká republika), Viiu-Marika RAND, Janika KORV, Manuel CAPPELLARI, Robert MIKULÍK (203 Česká republika, domácí), Danilo TONI a Niaz AHMED
Vydání
International Journal of Stroke, London, SAGE, 2023, 1747-4930
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 6.700 v roce 2022
Kód RIV
RIV/00216224:14110/23:00129975
Organizační jednotka
Lékařská fakulta
UT WoS
000798307100001
Klíčová slova anglicky
Stroke; statins; prevention; neuroprotection; severity; lipids
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 1. 2024 09:58, Mgr. Tereza Miškechová
Anotace
V originále
Background: Statins have an important role in stroke prevention, especially in high-risk populations and may also affect the initial stroke severity and outcomes in patients taking them before an ischemic stroke. Aims: Our aim was to evaluate the association of statin pre-treatment with the severity in acute ischemic stroke (AIS). Methods: We analyzed AIS patients received intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) and recorded in the SITS International Thrombolysis and Thrombectomy Registry from 2011 to 2017. We identified patients with statin information at baseline. The primary outcome was baseline National Institutes of Health Stroke Scale (NIHSS) score. Secondary outcomes were NIHSS score at 24 h, symptomatic intracerebral hemorrhage (SICH) and functional outcome at 90 days after acute intervention. Multivariable linear and logistic regression and propensity score matching (PSM) was used to quantify the effect of statin pre-treatment. Results: Of 93,849 patients, 23,651 (25.2%) were treated with statins prior the AIS. Statin pre-treatment group was older and had higher comorbidity. Median NIHSS at baseline was similar between groups. In the adjusted and PSM analysis, statin pre-treatment was inversely associated with baseline NIHSS (odds ratio (OR) = 0.77, 95% confidence interval (CI) = 0.6-0.99 and OR for PSM 0.73, 95% CI = 0.54-0.99, p = 0.004) and independently associated with mild stroke defined as NIHSS <= 8 in adjusted and PSM analysis (OR = 1.21, 95% CI = 1.1-1.34, p < 0.001 and OR for PSM 1.17, 95% CI = 1.05-1.31, p = 0.007). Regarding secondary outcomes, there were no differences in functional outcomes, death nor SICH rates between groups. Conclusion: Prior treatment with statins was associated with lower NIHSS at baseline. However, this association did not translate into any difference regarding functional outcome at 90 days. No association was found regarding SICH. These findings indicate the need of further studies to assess the effect on statin pre-treatment on initial stroke severity.